eISSN: 2083-8441
ISSN: 2081-237X
Pediatric Endocrinology Diabetes and Metabolism
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
 
3/2021
vol. 27
 
Share:
Share:
more
 
 
abstract:
Review paper

Mucopolysaccharidosis III: Molecular basis and treatment

Lidvana Spahiu
1
,
Emir Behluli
1
,
Borut Peterlin
2
,
Hilada Nefic
3
,
Rifat Hadziselimovic
3
,
Thomas Liehr
4
,
Gazmend Temaj
5

1.
Pediatric Clinic, University Clinical Center of Kosovo, Prishtina, Kosovo
2.
Department of Genetics and Genomics, University Clinical Center Ljubljana, Slovenia
3.
Faculty of Science, University of Sarajevo, Sarajevo, Bosnia and Herzegovina, Bosnia and Herzegovina
4.
Institut für Humangenetik, Universitätsklinikum Jena, Friedrich Schiller Universität, Jena Germany, Germany
5.
Human Genetics, College UBT, Faculty of Pharmacy Prishtina, Kosovo
Pediatr Endocrinol Diabetes Metab 2021; 27 (3): 201–208
Online publish date: 2021/09/30
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Mucopolysaccharidoses (MPSs) are known as rare genetic diseases which are caused by mutation in the enzyme heparin sulfate, which normally leads to degradation and accumulation of glycosaminoglycans in the cells. There are 11 types of MPSs, whereby neuropathy may occur in seven of them (MPS I, II, IIIA, IIIB, IIIC, IIID and VII). Accumulation of degraded heparin sulfate in lysosomes causes cellular dysfunction and malfunction of several organs. However, the exact molecular mechanism how protein degradation and storage leads to cellular dysfunction is not understood, yet. Nonetheless, several genetic and biochemical methods for diagnosis of MPSs are available nowadays. Here we provide an overview on known molecular basis of MPS in general, including enzyme defects and symptoms of MPS; however, the main focus is on MPS type III together with potential and perspective therapy-options.
keywords:

mucopolysaccharidosis III (MPS III), lysosomal storage diseases (LSDs), glycosaminoglycan, therapy for mucopolysccharidosis, clinical diagnosis



Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe